



S5 Fig. Effect size (beta) estimates and $-\log_{10} p$ -values for all significant oligopeptide variants for each drug, amikacin (AMI), bedaquiline (BDQ), clofazimine (CFZ), delamanid (DLM), ethambutol (EMB), ethionamide (ETH), isoniazid (INH), kanamycin (KAN), levofloxacin (LEV), linezolid (LZD), moxifloxacin (MXF), rifabutin (RFB) and rifampicin (RIF). For many of the drugs, the most significant oligopeptides were associated with lower MIC.